RhumbLine Advisers’s Perspective Therapeutics CATX Stock Holding History
Bought
Maintained
Sold
Other funds holding CATX
RhumbLine Advisers's CATX Position: Q3 2026 in Review
RhumbLine Advisers increased its Perspective Therapeutics (CATX) stake by 9.6% in Q3 2026, buying an estimated $35.8K and bringing the position to 135,118 shares worth $372K. The position accounts for ﹤0.01% of the portfolio, ranked #2906.
RhumbLine Advisers first reported a position in CATX in Q2 2024 and has held it in 10 quarters since. The position peaked at $1.21M in Q3 2024. 120 funds tracked by Wall St. Rank hold CATX as of Q3 2026.
- RhumbLine Advisers held 135,118 shares of Perspective Therapeutics worth $372K as of Q3 2026.
- RhumbLine Advisers bought 11,819 Perspective Therapeutics shares in Q3 2026, an estimated $35.8K.
- Perspective Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q3 2026, its #2906 holding.
- RhumbLine Advisers first reported a position in Perspective Therapeutics in Q2 2024 and has held it in 10 quarters since.
- RhumbLine Advisers's Perspective Therapeutics position peaked at $1.21M in Q3 2024.
- 120 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q3 2026.
Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.